News
MBIO
2.800
+6.06%
0.160
MUSTANG BIO INC - ESTIMATES $2 MILLION SAVINGS FROM LEASE TERMINATION
Reuters · 3d ago
Mustang Bio Sells Assets to AbbVie, Transfers Lease
TipRanks · 3d ago
Mustang Bio regains compliance with Nasdaq
TipRanks · 5d ago
MUSTANG BIO REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT
Reuters · 5d ago
MUSTANG BIO ANNOUNCES CLOSING OF $8 MILLION PUBLIC OFFERING
Reuters · 6d ago
Weekly Report: what happened at MBIO last week (0203-0207)?
Weekly Report · 6d ago
Mustang Bio Reports Pricing Of $8M Public Offering
Benzinga · 02/06 12:45
Mustang Bio prices 2.66M shares at $3.01 in public offering
TipRanks · 02/06 12:27
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Benzinga · 02/06 12:05
MUSTANG BIO INC - PRICES PUBLIC OFFERING OF 2,657,807 SHARES AT $3.01 PER SHARE
Reuters · 02/06 12:00
MUSTANG BIO ANNOUNCES PRICING OF $8 MILLION PUBLIC OFFERING
Reuters · 02/06 12:00
Weekly Report: what happened at MBIO last week (0127-0131)?
Weekly Report · 02/03 12:15
Weekly Report: what happened at MBIO last week (0120-0124)?
Weekly Report · 01/27 12:19
Weekly Report: what happened at MBIO last week (0113-0117)?
Weekly Report · 01/20 12:07
Mustang Bio trading halted, news pending
TipRanks · 01/16 00:51
Mustang Bio files to sell common stock, warrants
Seeking Alpha · 01/15 21:35
*Mustang Bio Offering Stock, Together With Accompanying Series C-1 Warrants, Series C-2 Warrants and Series C-3 Warrants
Dow Jones · 01/15 21:21
Mustang Bio files to sell common stock and warrants, no amount given
TipRanks · 01/15 21:20
Dow Gains Over 200 Points; Signet Jewelers Shares Plunge
Benzinga · 01/14 19:01
Crude Oil Down 1%; Firefly Neuroscience Shares Spike Higher
Benzinga · 01/14 17:25
More
Webull provides a variety of real-time MBIO stock news. You can receive the latest news about Mustang Bio through multiple platforms. This information may help you make smarter investment decisions.
About MBIO
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.